Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
Yasuhiro Nakamura(University of Tsukuba), N. Yamazaki, Satoshi Fukushima(Niigata Cancer Center Hospital), Yuki Shibayama(Kagawa University), Shigeto Matsushita(National Hospital Organization), Yukiko Kiniwa(Shinshu University), Kenji Yoshino(Tokyo Metropolitan Komagome Hospital), Naohito Hatta(Toyama Prefectural Central Hospital), Taiki Isei(Fukuoka University), Takeru Funakoshi(Keio University), Hisashi Uhara(Sapporo Medical University), Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Yukiko Teramoto(Asahikawa Medical University), Atsushi Otsuka(Kyoto University), Tatsuya Takenouchi(Niigata Cancer Center Hospital), Toshihiko Hayashi(Japan Institute of Leather Research), Dai Ogata(Unknown), Tsuyoshi Kawai(Nara Institute of Science and Technology), K. Goto(University of Tsukuba), Haruki Doi(Asahikawa Medical University), Shusuke Yoshikawa(Kyushu University), Hiroshi Uchi(Kyushu University)
Cited by 140
Related Papers
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
|Oncotarget|2016|160
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
|Journal of Dermatological Science|2015|120
Washout measurement of radioisotope implanted by radioactive beams in the rabbit
|Physics in Medicine and Biology|2003|113